* Gene Logic Inc., of Gaithersburg, Md., said it received a patent related to "differential display" genomics technology, which uses restriction enzymes that break up DNA into fragments that are separated by electrophoresis. Technology covered by U.S. Patent No. 5,814,445 can be used, for example, to study gene expression differences between normal and diseased tissues. Michael Brennan, the company's president and CEO, called the method "one of the key genomics technologies used today."
* Genome Therapeutics Corp., of Waltham, Mass., entered a licensing agreement with Hoechst Marion Roussel AG, of Frankfurt, Germany, under which Genome Therapeutics will provide Hoechst with nonexclusive access to PathoGenome, a microbial sequence database. Hoechst will pay annual subscription fees and royalties on any small molecules developed as a result of the subscription. Genome Therapeutics retains certain rights associated with the use of genes or gene products.
* Genset, of Paris, and Pharmacia & Upjohn, of Bridgewater, N.J., entered into a pharmacogenomics collaboration to discover markers and genes involved in response to a Pharmacia & Upjohn compound. The technology will be used to identify genetic markers among patients involved in clinical studies of the compound. Further details were not disclosed.
* Genzyme Corp., of Cambridge, Mass., said it will perform three supplemental environmental projects as part of a settlement with the New England office of the U.S. Environmental Protection Agency (EPA), in connection with an EPA enforcement action in January over waste documentation and procedural errors at Genzyme's Kendall Square and Binney Street facilities in Cambridge. Genzyme will implement a quality assessment of the Charles River watershed, help with a similar assessment of the Mystic River watershed, and install a hazardous waste management system, using the data gathered by the system to conduct pollution prevention and reduction assessments at the company's facilities in Cambridge, Allston and Framingham, Mass.
* ICN Pharmaceuticals Inc., of New York, signed an agreement with F. Hoffmann-La Roche Ltd., of Basel, Switzerland, to acquire worldwide rights to four Roche pharmaceutical products for $179 million. The drugs are Dalmadorn, for sleep disorders; Fluoro-Uracil, an oncology product; Librax, for gastrointestinal disorders; and Mogadon, a sleep disorder drug that is also used to treat epilepsy. The drugs generate $67 million in revenues annually.
* Immunicon Corp., of Huntingdon Valley, Pa., closed a convertible bridge loan for up to $1 million from MDS Capital Corp., of Canada. MDS and Immunicon are negotiating a round of venture capital equity financing to be led by MDS. The bridge loan is to be used until that financing is completed or other funding secured.
* Immunomedics Inc., of Morris Plains, N.J., said the FDA has given orphan drug designation to the company's CEA-Cide cancer therapeutic for use in non-small-cell lung cancer. CEA-Cide is a humanized monoclonal antibody.
* Incyte Pharmaceuticals Inc., of Palo Alto, Calif., was granted an exclusive license to pioneering gene expression analysis technology from the Montefiore Medical Center, in New York. The agreement grants Incyte exclusive sub-licensable rights to U.S. Patent No. 4,981,783. Filed in 1986 and issued in 1991, the patent includes claims that cover methods for measuring gene expression using a defined array.
* Lidak Pharmaceuticals Inc., of San Diego, filed a definitive proxy with the Securities and Exchange Commission relating to a proposal by the company's board of directors that would change Lidak's corporate name to Avanir Pharmaceuticals. The name change would have to be approved by shareholders, who are meeting on Nov. 20.
* Medarex Inc., of Annandale, N.J., said Centocor Inc., of Malvern, Pa., exercised its option to obtain exclusive commercial licenses to fully human antibodies to four antigens created with Medarex's HuMAb-Mouse technology. Under the terms of the agreement, Centocor has made a $4 million equity purchase and has received 900,340 shares of Medarex common stock.